Autologous transplantation for transformed non-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen.

Primary melanoma tumors from CDKN2A mutation carriers do not belong to a distinct molecular subclass.

Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma.

Molecular characterization of a heterothallic mating system in Pseudogymnoascus destructans, the Fungus causing white-nose syndrome of bats.

http://www.ncbi.nlm.nih.gov/books/NBK259289/

Assessment of PALB2 as a candidate melanoma susceptibility gene.

POT1 loss-of-function variants predispose to familial melanoma.

A phase I study of intravenous plerixafor following cyclophosphamide mobilization in patients with multiple myeloma.

Comorbidity burden in patients with chronic GVHD.

Prototype of an intertwined secondary-metabolite supercluster.